Brean Murray downgrades Halozyme Therapeutics, Inc. (Nasdaq: HALO) from Buy to Hold, saying while fundamentals are strong, the valuation is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE